PDCD1 and non-small cell lung carcinoma: In recent years, tumor immunotherapy has developed rapidly, and immune checkpoint inhibitors (ICIs), especially ICIs targeting programmed death factor-1 (PD-1) and programmed death ligand-1(PD-L1), have made breakthrough progress in the treatment of NSCLC with negative driver gene mutations, bringing survival benefits to patients and changing the treatment pattern of NSCLC [6].